^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CMD-602

    i
    Associations
    News

    Trials

    Company:
    Athenex, Baylor College of Medicine, Cell and Gene Therapy Catapult
    Drug class:
    Immunostimulant, Wilms tumor 1 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients (NCT02550535)
    Phase 1/2
    Cell Medica Ltd
    Completed
    Last update posted :
    10/02/2018
    Initiation :
    09/01/2015
    Primary completion :
    05/01/2018
    Completion :
    05/01/2018
    WT1
    |
    HLA-A*02:01
    |
    CMD-602